Get started
Zura Bio LimitedZura Bio LimitedZura Bio Limited

Zura Bio Limited

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

ZURA trade ideas

ZURA a med tech microcap with catalysts LONGZURA a penny stock has catalysts- an FDA action is soon upcoming and an insider bought a lot more shares. The 120-minute chart shows a solid trend up since earnings March 28th. This pre-revenue company beat earnings with less cash burn than expected. Another earnings report is about a month away. Price has settled to the support of the longest EMA line. I see an opportunity here for a long trade toward the earnings in a month. The longer black RSI line above the 50 level while the shorter green line shows the oversold undervalued condition for an entry.
NASDAQ:ZURALong
by AwesomeAvani
ZURA - Upcoming Catalysts comingZura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV. Disclaimer: This document is for informational purposes only and is not intended as financial advice. Please consult with a financial advisor before making any investment decisions. Investment Overview (As of April 27, 2024) Shares Information: Shares Float: 18.9 Million Relative Volume (Rel. Vol): 3.08 Insider Activity: Recent insider purchases noted, indicating potential confidence in the company’s future. Upcoming Corporate Events: Clinical Trials: Five trials scheduled for 2024. Financial Health: Strong liquidity position with substantial cash reserves and minimal debt. Key Technical Levels: Resistance Levels: Watch for $5.30, $6.30, $7.50, and $8.70. These points may offer opportunities for taking partial profits. Trading Strategy: Take Profit (TP): Set a profit target at approximately $11.00 to capitalize on earnings. Stop Loss (SL): Establish a stop loss order below $4.00 to limit potential losses. Chart Analysis: For a comprehensive analysis of price actions and trends, refer to the attached chart. Risk Advisory: Investing involves substantial risks. It is crucial to evaluate market conditions and your personal risk tolerance carefully. Conduct thorough research or consult with a financial advisor before making any trading decisions.
NASDAQ:ZURALong
by meitshels_smell_trades
ZURA, time to SEED the UPSIDE after a $80M financing.ZURA is registering massive massive volume based on weekly data. Volume net buys have increase two-folds from its average numbers, from 2.3M average volume to 5.7M last trading day. A huge hint of things to come for this stock after a FWB:80M financing for its Phase 2 clinical trial for ZB-106 in systemic sclerosis (SSc), followed by a Phase 2 clinical trial in hidradenitis suppurativa (HS). KEY NOTES: WEEKLY PRICE SHIFT HISTOGRAM SHIFT 1ST BUBBLE UP VOLUME in 3 months (bottom indicator) The chart is clean -- even without explaining it, you can DECIDE. :) Spotted at 7.0 TAYOR. Safeguard capital always. ---------------------------------------------- FUNDAMENTAL NEWS (Source YT site) Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist Total cash and cash equivalents of approximately $120 million is expected to fund planned clinical and operating activities through 2026 SAN DIEGO, June 06, 2023--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: "ZURA") ("Zura Bio"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the final closing of a private placement resulting in gross proceeds to Zura Bio of approximately $80 million. This funding will allow Zura Bio to initiate a Phase 2 clinical trial for ZB-106 in systemic sclerosis (SSc), followed by a Phase 2 clinical trial in hidradenitis suppurativa (HS). ZB-106 currently has clinical data from two Phase 1b studies completed in rheumatoid arthritis and Sjögren's syndrome. The safety profile to date appears to be acceptable, with no new findings relative to known IL-17 and BAFF inhibitors. Chronic toxicology studies have been completed with no adverse drug-related findings. "To complete the financing is a key milestone. Not just for Zura Bio as a company, but for the development of our ZB-106 asset and the benefits that we hope it can bring to patients. Achieving our cash targets puts us in a great position to progress important clinical development programs and we are excited to move our operations forward as a result." said Dr. Someit Sidhu, Chief Executive Officer and Director of Zura Bio.
NASDAQ:ZURALong
by JSAL
1